![](https://img6.s3wfg.com/web/img/images_uploaded/8/4/dl-astrazeneca-ftse-100-astra-zeneca-health-care-healthcare-pharmaceuticals-and-biotechnology-pharmaceuticals-logo.jpg)
AstraZeneca posts mixed results from recent Imfinzi trials
The FTSE 100 pharmaceuticals giant said the ADJUVANT BR.31 trial, sponsored by the Canadian Cancer Trials Group (CCTG), investigated Imfinzi in early-stage non-small cell lung cancer (NSCLC). It said the trial did not achieve statistical significance in …